Unknown PHASE4 INTERVENTIONAL 2-arm NCT04197050

Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD (EARLY-MYO-CTD)

Effect of Sacubitril/Valsartan on Right Ventricular Dysfunctioning Patients With Connective Tissue Disease

Sponsor: RenJi Hospital

Conditions Connective Tissue Diseases Myocardial Injury

Interventions Sacubitril / Valsartan Oral Tablet

Updated 6 times since 2020 Last updated: Jan 4, 2020 Started: Feb 20, 2020 Primary completion: Nov 30, 2022 Completion: Nov 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04197050, this PHASE4 trial focuses on Connective Tissue Diseases and Myocardial Injury and remains ongoing. Sponsored by RenJi Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Dec 2022 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Dec 2022 [monthly]

Not Yet Recruiting PHASE4
Feb 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Jan 2020 — Feb 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China